Inception 5 Inc.

The second quarter was a record-breaking period with China-focused biopharma start-ups and others raising hundreds of millions of dollars in venture capital. Both the amount of money raised and the nu

Necessity mothered the build-to-buy strategy. Some thought good times might kill it. At a time when venture capital found few exit opportunities for early-stage companies, build-to-buy helped mitigate

Series A financings for biopharma, medtech, and diagnostics start-ups totaled $627.5 million in the first half of 2014. That’s 8% less than the same period last year, when the half-year figure stood a

Financings During the second quarter of 2014 start-up companies raised a total of $893.9 million, a 25% drop from the previous quarter’s $1.18 billion, which was the biggest quarter for start-up fundr